Ifp Advisors, Inc I Mab Transaction History

Ifp Advisors, Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 06, 2021	SELL	$57.18 - $84.43 $20,070 - $29,634	-351 Closed	0 $0
Q2 2021 Jul 13, 2021	SELL	$47.86 - $83.95 $7,179 - $12,592	-150 Reduced 29.94%	351 $29,000
Q1 2021 Apr 30, 2021	SELL	$44.38 - $63.97 $621 - $895	-14 Reduced 2.72%	501 $24,000
Q4 2020 Jan 25, 2021	BUY	$32.94 - $47.15 $1,284 - $1,838	39 Added 8.19%	515 $25,000
Q3 2020 Oct 29, 2020	BUY	$27.46 - $47.03 $13,070 - $22,386	476 New	476 $23,000

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $74.8M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ifp Advisors, Inc with notifications on news.